Transparency Document
NCCN Guidelines for Biliary Tract Cancers V.5.2024
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 4752 - Internal Request | BIL-C 3 of 5 | Based on the FDA approval of zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, include zanidatamab-hrii as a category 2A, useful in certain circumstances recommendation. | Change made | This is a category 2A recommendation. See submission for references. |
Yes: 26 No: 0 Abstain:0 Absent:8 |
| 4513 |
BIL-C 3 of 5 (Principles of Systemic Therapy – Target Therapy)
Zanidatamab Submission from Jazz Pharmaceuticals on 09-05-2024 |
Under HER2-positive tumors, please add zanidatamab as an option (please consider placing as a top option based on the largest BTC-specific data set for HER2 therapy in an earlier line than current options). | Change not made | Refer to Internal request 4752 for vote and details under Comment on Panel Decision. |
Yes: 0 No: 0 Abstain:0 Absent:0 |